Current Report Filing (8-k)
April 07 2021 - 6:45AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
April
5, 2021
AIM
IMMUNOTECH INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001
– 27072
|
|
52-0845822
|
(state or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
2117
SW Highway 484, Ocala FL
|
|
34473
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code: (352) 448-7797
AIM
ImmunoTech Inc.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
|
AIM
|
|
NYSE
American
|
Item
1.01 Entry into a Material Definitive Agreement
AIM
ImmunoTech Inc. (“AIM” or “Company”) has recently entered into two agreements.
On
April 5, 2021, the Company approved a proposal from Polysciences Inc. (“Polysciences”) for the manufacture of AIM’s
Poly I and Poly C12U polynucleotides and associated test methods at Polysciences’ Warrington, Penn. location to enhance
the Company’s capacity to produce the polymer precursors to the drug Ampligen. The Company is working with Polysciences
to finalize a Service Agreement and a Quality Agreement.
On
April 5, 2021, the Company entered into a Material Transfer and Research Agreement (MTA) with the University of Cagliari Dipartimento
di Scienze della Vita e dell’Ambiente (UNICA), an educational institution under the laws of Italy, located in Monserrato
(Cagliari), Italy. The MTA relates to the research and development of the effects of AIM’s drug Ampligen and its ability
to induce interferon production in several cell lines and also on the ability of the Ebola virus protein VP35 to bind to viral
dsRNA and impede interferon’s upregulation and activity, and on Ampligen’s ability to reverse VP35 inhibition of interferon
production in biological systems.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AIM
IMMUNOTECH INC.
|
|
|
April
7, 2021
|
By:
|
/s/
Thomas K. Equels
|
|
|
Thomas K. Equels, CEO
|
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Apr 2024 to May 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From May 2023 to May 2024